TABLE 1.
Specific objectives recorded in the forefront of developing ICPs for AD.
|
1 |
To compile a brief and concise tool that is easy to understand for people with and without medical background |
|
2 |
To give an overview of the existing guidelines, consensus statements and ICPs as well as real‐world data |
|
3 |
To focus on the present situation and evidence but also to include visions for the future |
|
4 |
To strengthen prevention and health promotion for AD |
|
5 |
To mainly cover diagnostic and treatment of patients with AD, aiming to discuss detailed guidance on prevention and health promotion separately |
|
6 |
To aid the diagnosis of AD |
|
7 |
To provide a structured approach to treatment strategies including OTC therapies, with a focus on the interventions that are mainly used |
|
8 |
To consider all AD comorbidities as significant, such as psychiatric morbidity. This is seen not only in severe AD but also in moderate AD. As an example, ocular morbidity can exist in patients with only eyelid dermatitis (very low EASI) |
|
9 |
To have a particular focus on mild to moderate AD, as severe AD is already covered in detail in AD guidelines. The ICPs will refer to these when appropriate |
|
10 |
To stratify patients with severe AD |
|
11 |
To understand AD and the different comorbidities in subgroups such as children, adolescents and older people, and to develop relevant criteria to guide their management |
|
12 |
To understand and overcome barriers in a holistic patient‐centred approach managing AD, including somatic, psychosomatic and psychiatric comorbidities such as anxiety and depression as well as the impact of the disease on work |
|
13 |
To investigate and consider different practices in different countries, for example, the role of pharmacists in patient care |
|
14 |
To consider all parties involved in the patients' care, including the role of para‐medical staff such as physician assistants, dermatological nurses, nurse specialists, social workers and assistants in the GP's office, considering their roles, limitations and their place within the multidisciplinary team |
|
15 |
To specifically develop a unique educational module for pharmacists on AD recognition, the use of emollients, specific treatments and disease monitoring. As a first step, the role of the pharmacist in patient management needs to be identified in different countries |
|
16 |
To develop ICPs for rhinitis, asthma and ocular comorbidity across the life cycle in AD, inter linking with the existing AIRWAYS ICPs |
|
17 |
To determine whether mobile health tools like MASK‐air for rhinitis and asthma comorbidity could be applied, redesigning care pathways also for AD patients |
|
18 |
To investigate and discuss unmet needs such as the cultural and social aspects of the disease starting in childcare and school but also in nursing homes, in a project centred on the patient |
|
19 |
To implement multi‐sectoral, multi‐country initiatives involving the ADCARE network, creating solutions for trials and registries to investigate real‐life settings |
Abbreviations: EASI, Eczema Area and Severity Index; GP, general practitioner; MASK, Mobile Airways Sentinel Network; OTC, over the counter.